Cargando…
The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses
An epidemiological model for COVID-19 was developed and implemented in MATLAB/GNU Octave for use by public health practitioners, policy makers, and the general public. The model distinguishes four stages in the disease: infected, sick, seriously sick, and better. The model was preliminarily paramete...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416305/ https://www.ncbi.nlm.nih.gov/pubmed/32836820 http://dx.doi.org/10.1007/s11071-020-05861-7 |
_version_ | 1783569302179282944 |
---|---|
author | De Visscher, Alex |
author_facet | De Visscher, Alex |
author_sort | De Visscher, Alex |
collection | PubMed |
description | An epidemiological model for COVID-19 was developed and implemented in MATLAB/GNU Octave for use by public health practitioners, policy makers, and the general public. The model distinguishes four stages in the disease: infected, sick, seriously sick, and better. The model was preliminarily parameterized based on observations of the spread of the disease. The model assumes a case mortality rate of 1.5%. Preliminary simulations with the model indicate that concepts such as “herd immunity” and containment (“flattening the curve”) are highly misleading in the context of this virus. Public policies based on these concepts are inadequate to protect the population. Only reducing the R(0) of the virus below 1 is an effective strategy for maintaining the death burden of COVID-19 within the normal range of seasonal flu. The model is illustrated with the cases of Italy, France, and Iran and is able to describe the number of deaths as a function of time in all these cases although future projections tend to slightly overestimate the number of deaths when the analysis is made early on. The model can also be used to describe reopenings of the economy after a lockdown. The case mortality rate is still prone to large uncertainty, but modeling combined with an investigation of blood donations in The Netherlands imposes a lower limit of 1%. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11071-020-05861-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7416305 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-74163052020-08-10 The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses De Visscher, Alex Nonlinear Dyn Original Paper An epidemiological model for COVID-19 was developed and implemented in MATLAB/GNU Octave for use by public health practitioners, policy makers, and the general public. The model distinguishes four stages in the disease: infected, sick, seriously sick, and better. The model was preliminarily parameterized based on observations of the spread of the disease. The model assumes a case mortality rate of 1.5%. Preliminary simulations with the model indicate that concepts such as “herd immunity” and containment (“flattening the curve”) are highly misleading in the context of this virus. Public policies based on these concepts are inadequate to protect the population. Only reducing the R(0) of the virus below 1 is an effective strategy for maintaining the death burden of COVID-19 within the normal range of seasonal flu. The model is illustrated with the cases of Italy, France, and Iran and is able to describe the number of deaths as a function of time in all these cases although future projections tend to slightly overestimate the number of deaths when the analysis is made early on. The model can also be used to describe reopenings of the economy after a lockdown. The case mortality rate is still prone to large uncertainty, but modeling combined with an investigation of blood donations in The Netherlands imposes a lower limit of 1%. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11071-020-05861-7) contains supplementary material, which is available to authorized users. Springer Netherlands 2020-08-10 2020 /pmc/articles/PMC7416305/ /pubmed/32836820 http://dx.doi.org/10.1007/s11071-020-05861-7 Text en © Springer Nature B.V. 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Paper De Visscher, Alex The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses |
title | The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses |
title_full | The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses |
title_fullStr | The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses |
title_full_unstemmed | The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses |
title_short | The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses |
title_sort | covid-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416305/ https://www.ncbi.nlm.nih.gov/pubmed/32836820 http://dx.doi.org/10.1007/s11071-020-05861-7 |
work_keys_str_mv | AT devisscheralex thecovid19pandemicmodelbasedevaluationofnonpharmaceuticalinterventionsandprognoses AT devisscheralex covid19pandemicmodelbasedevaluationofnonpharmaceuticalinterventionsandprognoses |